Christian Jacquelinet
Overview
Explore the profile of Christian Jacquelinet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
1203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laville S, Vendar J, Massy Z, Gras-Champel V, Moragny J, Frimat L, et al.
Clin Kidney J
. 2025 Jan;
18(1):sfae357.
PMID: 39781474
Background: We sought to comprehensively describe drug-related components associated with acute kidney injury (AKI) in patients with chronic kidney disease (CKD), describing the incidence of drug-related AKI, the proportion of...
2.
Mouheb A, Lambert O, Alencar De Pinho N, Jacquelinet C, Laville M, Combe C, et al.
J Nephrol
. 2025 Jan;
PMID: 39775518
Background: Hyperuricemia is a hallmark of gout and a suspected risk factor for the progression of chronic kidney disease (CKD). However, the impact of urate-lowering therapy on CKD progression is...
3.
Cseprekal O, Jacquelinet C, Massy Z
Clin Kidney J
. 2024 Dec;
17(12):sfae335.
PMID: 39698373
Pre-emptive kidney transplantation (PKT) has long been considered the optimal treatment for patients with end-stage chronic kidney disease (CKD) seeking the most favourable long-term outcomes. However, the significant growth in...
4.
Mouheb A, Levassort H, Massy Z, Jacquelinet C, Laville M, Alencar De Pinho N, et al.
J Am Geriatr Soc
. 2024 Nov;
73(2):533-544.
PMID: 39605299
Background: People with chronic kidney disease (CKD) have an elevated risk of cognitive impairment (CI). Medications with anticholinergic activity are recognized for their adverse reactions on central nervous system. The...
5.
Costes-Albrespic M, Liabeuf S, Laville S, Jacquelinet C, Combe C, Fouque D, et al.
Kidney Med
. 2024 Nov;
6(12):100912.
PMID: 39574792
Rationale & Objective: Blood pressure (BP) control is essential for preventing cardiorenal complications in chronic kidney disease (CKD), but most patients fail to reach BP target. We assessed longitudinal patterns...
6.
Levassort H, Boucquemont J, Lambert O, Liabeuf S, Laville S, Teillet L, et al.
Toxins (Basel)
. 2024 Jul;
16(7).
PMID: 39057966
Depression is common in patients with chronic kidney disease (CKD). Experimental studies suggest the role of urea toxicity in depression. We assessed both the incidence of antidepressant prescriptions and depressive...
7.
Pluquet M, Metzger M, Jacquelinet C, Combe C, Fouque D, Laville M, et al.
Front Pharmacol
. 2024 Jul;
15:1375838.
PMID: 39027337
Adjusting drug dose levels based on equations that standardize the estimated glomerular filtration rate (eGFR) to a body surface area (BSA) of 1.73 m can pose challenges, especially for patients...
8.
Faucon A, Lambert O, Massy Z, Drueke T, Combe C, Fouque D, et al.
Am J Kidney Dis
. 2024 Jun;
84(5):546-556.e1.
PMID: 38925506
Rationale & Objective: Sex differences in cardiovascular disease (CVD) are well established, but whether chronic kidney disease (CKD) modifies these risk differences and whether they differ between atheromatous CVD (ACVD)...
9.
Goutaudier V, Sablik M, Racape M, Rousseau O, Audry B, Kamar N, et al.
Eur J Epidemiol
. 2024 Apr;
39(5):549-564.
PMID: 38625480
There is an unmet need for robust and clinically validated biomarkers of kidney allograft rejection. Here we present the KTD-Innov study (ClinicalTrials.gov, NCT03582436), an unselected deeply phenotyped cohort of kidney...
10.
Lamarque C, Segaux L, Bachellier P, Buchard B, Chermak F, Conti F, et al.
J Hepatol
. 2024 Mar;
81(2):278-288.
PMID: 38521171
Background & Aims: To maximize utility and prevent premature liver transplantation (LT), a delayed LT strategy (DS) was adopted in France in 2015 in patients listed for any single HCC...